
Opinion|Videos|October 8, 2024
Unmet Needs in the HFmrEF and HFpEF Landscape
Author(s)Javed Butler, MD, MPH, MBA
Key Takeaways
- Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations.
- Emerging treatments could reduce hospitalization rates and enhance quality of life for patients with HFmrEF and HFpEF.
Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients with nondiabetic heart failure, including the study’s objective, design, methodology, results, and key clinical implications for the use of dapagliflozin in this population.
Advertisement
Video content above is prompted by the following:
- Based on the new data from the 3 abstracts, what unmet needs could the therapies address within the heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF landscape?
Advertisement
Related to this article

Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.

Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.

Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.

A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.

Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.

The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.

Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
3
Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts
4
UPMC Health Plan's Food as Medicine Pilot for Members With Diabetes
5

